Онлайн КрасотаКаталог

Брошюра «Клинические исследования пептидных биорегуляторов» Электронная версия на английском языке — страница 10

Книги и пособия · 125 страниц · 0.7 МБ · Полное издание

Читать текстСкачать PDF
Bonothyrk® The state of the bone tissue was determined by the method of X-ray densitometry and by observing the dynamics of the decrease in bone mineral density - before the start of treatment and 3 months after the end of the course of using BONOTHYRK®. RESEARCH RESULTS The use of BONOTHYRK® in patients with an initially reduced indicator of bone mineral density (BMD) contributed to the prevention of the progression of bone tissue demineralization (table). Dynamics of bone mineral density in patients with climacteric syndrome Table Decreased BMD Number of patients,% Initial level After 3 months. After 3 months using BONOTHYRK® (control group) (main group) 15-20% 90,5 85,6 94,7 20-25% 9,5 14,4 5,3 * p <0.05 reliablein comparison with the indicator in patients before treatment; # p <0.05 reliable in comparison with the indicator in patients after treatment with conventional means. As you can see from the data shown in the table, at the end of the course with BONOTHYRK®, the progression of the decrease in bone mineral density in patients of the primary group slowed down. The number of patients who had a decrease in BMD of no more than 20% increased from 90.5% (initially) to 94.7% after the course of treatment, which indicates an emerging trend of inhibition of the process of bone demineralization. In the control group patients who did not take drugs aimed at inhibiting the process of bone demineralization, the number of patients with a decrease in bone mineral density of more than 20% increased from 9.5% (initially) to 14.4% after 3 months, which creates an unfavorable prognosis in terms of the development of osteoporosis. Thus, the obtained results of the study indicate the preventive and therapeutic efficacy of BONOTHYRK® and the advisability of its use in the complex treatment of patients of different ages who are at risk of developing osteoporosis. When using BONOTHYRK®, no side effects, complications, or drug dependence were observed. BONOTHYRK® can be used for therapeutic and prophylactic purposes in the form of a biologically active food supplement combined with any means of symptomatic and pathogenetic therapy used to treat osteoporosis. CONCLUSION Biologically active food supplement BONOTHYRK® has a normalizing effect on the functional activ- ity of bone cells. BONOTHYRK® is well tolerated when taken orally, has no side effects, and can be used as a thera- peutic and prophylactic biologically active food supplement. BONOTHYRK® is recommended for the complex treatment of patients with early-stage osteoporo- sis, orally during meals, 1-2 capsules 2 times a day for at least 30 days. It is recommended to repeat the course of treatment after 3-6 months.

Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.

Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.